PUBLIC COMPANY
save$RYTMRHYTHM PHARMACEUTICALS, INC.
$RYTM95.71-2.89%Boston, MA, USupdated 48m ago
community read0 votes
pipeline
4
marketed
1
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Phase 21Marketed1Unknown
Upcoming
Recent(90d)
earnings (1)
Active trials
- phase3A Trial of Setmelanotide in Acquired Hypothalamic Obesity
- phase3Open-Label Extension Study of Setmelanotide
- phase2A Study of Setmelanotide in Patients With Prader-Willi Syndrome
- phase2A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
- phase3A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
- phase2A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
- phase3EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
- phase2A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
🐶 Hiring Signal
next earnings Nov 3, 2026
News
- Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataPlus news about Sanofi, PharmaMar, Jazz, Rhythm Pharmaceuticals, Spyre and Zymeworks 🇨🇳 Another obesity readout from China: Gan & Lee Pharmaceuticals, a China-based insulin specialist, announced…endpoints · 3mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that